| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 24th September 2020 | Randal J Kirk | 21,428 | Grant/award etc. | $3.50 | $74,998.00 |
| 12th August 2020 | Randal J Kirk | 10,779 | Open or private purchase | $4.26 | $45,918.54 |
| 12th August 2020 | Randal J Kirk | 10,775 | Open or private purchase | $4.26 | $45,901.50 |
| 12th August 2020 | Randal J Kirk | 30,514 | Open or private purchase | $4.26 | $129,989.64 |
| 12th August 2020 | Randal J Kirk | 29,652 | Open or private purchase | $4.26 | $126,317.52 |
| 12th August 2020 | Randal J Kirk | 8,952 | Open or private purchase | $4.26 | $38,135.52 |
| 12th August 2020 | Randal J Kirk | 278,921 | Open or private purchase | $4.26 | $1,188,203.46 |
| 12th August 2020 | Randal J Kirk | 1,664 | Open or private purchase | $4.26 | $7,088.64 |
| 12th August 2020 | Randal J Kirk | 1,993 | Open or private purchase | $4.26 | $8,490.18 |
| 12th August 2020 | Randal J Kirk | 10,792 | Open or private purchase | $4.26 | $45,973.92 |
Histogenics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 3/10.
Histogenics Corp. engages in the development, marketing, and commercialization of restorative cell therapies. The company was founded on June 28, 2000 and is headquartered in Waltham, MA.
Ticker: HSGX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1372299
Employees: 49
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Restructuring Charges of $700 Th for the period Apr 2020 to Jun 2020 in the context of Employee severance
Restructuring Charges of $200 Th for the period Apr 2020 to Jun 2020 in the context of Employee severance
Restructuring Charges of $500 Th for the period Apr 2020 to Jun 2020 in the context of Research and development expense
Restructuring Charges of $700 Th for the period Jan 2020 to Jun 2020 in the context of Employee severance
Restructuring Charges of $200 Th for the period Jan 2020 to Jun 2020 in the context of Employee severance
Restructuring Charges of $500 Th for the period Jan 2020 to Jun 2020 in the context of Research and development expense
Restructuring Charges of $694 Th for the period Jan 2020 to Jun 2020 in the context of Employee severance
Fundamentals
Cash at Carrying Value: $15 M (0%)
Assets, Current: $23 M (45%)
Property, Plant and Equipment, Net: $232 Th (4%)
Other Assets, Noncurrent: $483 Th (-27%)
Assets: $24 M (41%)
Accounts Payable, Current: $508 Th (-73%)
Accrued Liabilities, Current: $2 M (0%)
Liabilities, Current: $7 M (54%)
Long-term Debt, Excluding Current Maturities: $2 M (88%)
Other Liabilities, Noncurrent: $0 (-100%)
Liabilities: $9 M (57%)
Common Stock, Value, Issued: $1 M (156%)
Common Stock, Shares, Issued: $135 M (156%)
Retained Earnings (Accumulated Deficit): $59 M (0%)
Treasury Stock, Value: $479 Th (0%)
Stockholders' Equity (Parent): $15 M (0%)
Liabilities and Equity: $24 M (41%)
General and Administrative Expenses: $2 M (-56%)
Operating Income/Loss: $3 M (-53%)
Other Income, net: $248 Th (-5%)
News
Here are five stocks to own for the 5G network buildout
19th October 2020
IBM revenue edges past estimates on cloud strength
19th October 2020
International Business Machines Corp. Stock Quote (U.S.: NYSE)
19th October 2020
